Immuneering Announces Clinical Supply Agreement With Eli Lilly To Evaluate Atebimetinib In Combination With Olomorasib

Immuneering Corporation, a clinical-stage oncology company focused on developing therapies to extend the lives of cancer patients, announced that it has entered into a clinical supply agreement with Eli Lilly and Company for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982). The collaboration will support the evaluation of Immuneering’s lead investigational therapy, atebimetinib (IMM-1-104), a novel dual MEK inhibitor, in combination with olomorasib in a planned Phase 2 clinical trial. 

The trial will enroll patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC) who have progressed after prior therapies. The planned Phase 2 study will assess whether the combination of atebimetinib with olomorasib can improve outcomes in this difficult-to-treat patient population. Atebimetinib, Immuneering’s lead clinical candidate, is designed to inhibit MEK activity in a highly selective and controlled manner, with the goal of improving tolerability while maintaining anti-tumor activity. 

E.B. Brakewood Chief Business Officer of Immuneering, stated, “This agreement with Lilly marks the second such collaboration we have announced this year as we seek to evaluate the potential of atebimetinib in combination with synergistic anti-cancer mechanisms. A pan-MAPK solution is of particular interest in challenging tumor types such as NSCLC.”

Igor Matushansky, MD, PhD, Chief Medical Officer of Immuneering, “The combination of atebimetinib and olomorasib has the potential to provide a vertical blockade of the RAS-MAPK pathway, which is supported by preclinical studies of this combination in which enhanced tumor regression, delayed emergence of tumor resistance and prolonged survival relative to monotherapy was observed. This dual targeted approach has the potential to improve outcomes in a population with limited effective treatment options.”

By combining atebimetinib with Lilly’s targeted KRAS G12C inhibitor, the program aims to explore a synergistic approach to blocking cancer-driving pathways in NSCLC. This new agreement with Lilly follows Immuneering’s previously announced partnership with Regeneron Pharmaceuticals in February 2025. Under that collaboration, atebimetinib is being evaluated in combination with Regeneron’s anti-PD-1 therapy, Libtayo® (cemiplimab), in patients with advanced non-small cell lung cancer. 

Together, these efforts reflect Immuneering’s strategy of advancing atebimetinib in multiple combination approaches to broaden potential treatment options across different subgroups of lung cancer patients. Importantly, Immuneering will retain global development and commercialization rights to atebimetinib, underscoring the company’s commitment to building a pipeline of innovative oncology therapies with long-term strategic value.